Axsome Therapeutics gained 1.70% in the last trading day ( Friday, Nov 29), increasing from $38.71 to $ 39.37. Will the company be able to continue growing?
By Guy Avtalyon
Axsome Therapeutics is developing innovative therapies for the treatment of CNS disorders. Yes, clinical-stage biotech stocks can be a risky suggestion for investors. Well, at the same time this stock is extremely suitable for any dynamic investors. If you prefer an aggressive approach to your investment this stock deserves your attention.
Axsome Therapeutics (AXSM) has jumped over 1.200% in this year. The investors are awaiting the biotech’s upcoming clinical study results excited. Well, the company is in a late-stage study for its AXS-05. It is innovative and important in treating a depressive disorder, so-called MDD to the end of the year. The company is awaiting results from another study, a drug for treating treatment-resistant depression and it will be published to the end of the first quarter in 2020. Also, Axsome Therapeutics expects to present excellent results from a study of AXS-05 for Alzheimer’s disease in the first six months of 2020.
To the end of this year, the company is expected to present the results from a late-stage study of AXS-07 in treating migraine and of AXS-12 in treating narcolepsy. Analysts estimate AXS-05 could obtain annual sales of more than $1 billion when approved.
The main problem is that Axsome Therapeutics’ results could be failed like it is with so many drugs.
But if they get a good result this stock will be high rocketed.
The current price is $39.37 (Nov 29). This small-cap stock in the S&P 500 had the greatest total return over the past 12 months. It is 959.6%
Why invest in Axsome Therapeutics
Axsome Therapeutics, Inc can be a profitable investment option for investors wanting good returns. Axsome Therapeutics, Inc quote is $39.370 on December 2. This stock can provide more than 300% of revenue after 5 years since it is expected the price to rise to $160 in the next year.
Axsome Therapeutics has a median target of $46.50, where a high estimate of $53.00 and a low estimate of $25.00. The median estimate represents a +18.11% jump from the current price. The investment analysts’ suggestion is to buy this stock.
Axsome Therapeutics ABOUT
The company’s market cap is $1.36B. Axsome Therapeutics reported Q3 2019 financial results on Nov 7, 2019.
Axsome Therapeutics is a clinical-stage biopharmaceutical company that develops innovative treatments for CNS disorders, especially for those with limited treatment possibilities. Axsome’s center CNS product portfolio covers four clinical-stage products, AXS-05, AXS-07, AXS-09, and AXS-12. AXS-05 is in a phase 3 test in treatment-resistant depression, the same as MDD, and a Phase 2/3 trial in difficulties connected with Alzheimer’s disease. AXS-05 is also being developed for smoking end therapy. AXS-07 is in two Phase 3 trials for the treatment of migraine. AXS-12 is in a Phase 2 trial in narcolepsy.
AXS-05, AXS-07, AXS-09, and AXS-12 are drug products not approved by the FDA. For more specific information, you have to visit the company’s website. The Company may occasionally disseminate material, nonpublic information on the company website.
Is AXSM a good investment?
This company’s liquidity data is interesting: its Quick Ratio is 1.41 and its Current Ratio is 1.41. This shows a good ratio between its short-term liquid assets and its short-term liabilities. So we can easily conclude it is a less risky investment. This stock’s RSI score is at 50.78, which means that the stock is not oversold or overbought.
The important clinical wins could place this company on the route to produce greater gains. Hence, we think it is a good investment.